Prevalence of Thrombophilic Gene Polymorphism (MTHFR C677T) in COVID-19patients

Plain-language summary

This study investigated how often the MTHFR C677T gene polymorphism (a genetic change linked to a tendency for blood clotting) occurs in COVID-19 patients. MTHFR C677T genotypes were determined from a blood sample using RT-PCR, and the study enrolled adults over 18 diagnosed with COVID-19 by RT-PCR. It was a trial without an assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Ain Shams University

Intervention

RT- PCR of 2 ml EDTA blood sample to determine MTHFR C677T genotypes

Start date

5/11/2022

Estimated completion

11/30/2022

Countries

Egypt

Related genes

Locations

• Cairo, Egypt

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* All adult patients diagnosed as COVID -19 by RT-PCR will be included

Exclusion Criteria:

* Patients younger than 18 years old Patients on Antithrombotic treatment before COVID-19.